Latest news
21.01.2021
DEINOVE strenghtens its Business development team to deploy its partnering strategy
Hervé Ansanay, PhD, former Technology transfer and Business Development Director of the SATT AxLR of Montpellier, is appointed Business...
20.01.2021
Issuance of a 5th tranche of 3 millions EUR of notes convertible into new shares
DEINOVE strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe gastrointestinal...
11.01.2021
Alexis RIDEAU appointed CEO of DEINOVE
Alexis RIDEAU, Deputy Chief Executive Officer of DEINOVE since May 2020, is now the Chief Executive Officer of the Company. Charles WOLER,...
Press Coverage
12.05.2020
Cdiff Foundation | A New Parenteral Treatment for a Severe C. difficile Infection
"A New Parenteral Treatment for a Severe C. difficile Infection" hosted by Nancy C. Caralla Join us with our two guests: Dr Yannick Pletan...
08.05.2020
Biotech & Finance | Alexis Rideau, arrive chez Deinove avec son réseau industriel et académique de pointe
C’est une nouvelle aventure pour Alexis Rideau, qui occupe depuis cette semaine la fonction de directeur général délégué de Deinove...
06.05.2020
La Tribune | Deinove recrute Alexis Rideau, nouveau DG délégué
Deinove, société montpelliéraine de biotechnologie développant des antibiotiques novateurs et des actifs biosourcés pour la cosmétique et...